Enhancement of tumor‐associated antigen‐specific T cell responses by radiofrequency ablation of hepatocellular carcinoma

• Published in: Hepatology (Baltimore, Md.) Vol. 57; no. 4; pp. 1448 - 1457
• Main Authors: Mizukoshi, Eishiro, Yamashita, Tatsuya, Arai, Kuniaki, Sunagozaka, Hajime, Ueda, Teruyuki, Arihara, Fumitaka, Kagaya, Takashi, Yamashita, Taro, Fushimi, Kazumi, Kaneko, Shuichi
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2013; Wiley Subscription Services, Inc
• Subjects: Aged; Antigens, Neoplasm - metabolism; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - surgery; Catheter Ablation; Female; Hepatology; Histocompatibility Antigens Class II - metabolism; Humans; Immune system; Immunology; Kaplan-Meier Estimate; Liver Neoplasms - immunology; Liver Neoplasms - pathology; Liver Neoplasms - surgery; Male; Medical research; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Phenotype; Prognosis; Survival Rate; T-Lymphocytes - immunology; T-Lymphocytes - pathology; Tumors

Radiofrequency ablation (RFA) is one of the treatments for hepatocellular carcinoma (HCC) and is known to enhance host immune response. However, the epitopes to which enhanced immune responses occur, the impact on patient prognosis, and the functions and phenotype of T cells induced are still unclea...